BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31711337)

  • 41. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.
    Zhou S; Tremblay D; Hoffman R; Kremyanskaya M; Najfeld V; Li L; Moshier E; Mascarenhas J
    Acta Haematol; 2021; 144(1):48-57. PubMed ID: 32160610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
    Mazza P; Specchia G; Di Renzo N; Cascavilla N; Tarantini G; Capalbo SF; Urbano T; Albano F; Giovannni R; Falcone AP; Santeramo MT; Spinosa G; Pisconti S
    Leuk Lymphoma; 2017 Jan; 58(1):138-144. PubMed ID: 27263544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):277-86. PubMed ID: 25696867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
    Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
    Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of JAK2 inhibitors in MPNs 7 years after approval.
    Passamonti F; Maffioli M
    Blood; 2018 May; 131(22):2426-2435. PubMed ID: 29650801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
    Mesa RA; Scherber RM; Geyer HL
    Leuk Lymphoma; 2015 Jul; 56(7):1989-99. PubMed ID: 25644746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
    Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
    BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
    Masarova L; Bose P; Verstovsek S
    Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
    Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.
    Lee SS; Verstovsek S; Pemmaraju N
    J Immunother Precis Oncol; 2021 Aug; 4(3):117-128. PubMed ID: 35663101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
    Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
    Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
    Polverelli N; Elli EM; Abruzzese E; Palumbo GA; Benevolo G; Tiribelli M; Bonifacio M; Tieghi A; Caocci G; D'Adda M; Bergamaschi M; Binotto G; Heidel FH; Cavazzini F; Crugnola M; Pugliese N; Bosi C; Isidori A; Bartoletti D; Auteri G; Latagliata R; Gandolfi L; Martino B; Scaffidi L; Cattaneo D; D'Amore F; Trawinska MM; Stella R; Markovic U; Catani L; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Vianelli N; Breccia M; Russo D; Cavo M; Iurlo A; Palandri F
    Br J Haematol; 2021 Apr; 193(2):356-368. PubMed ID: 33222197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations.
    Sadjadian P; Wille K; Griesshammer M
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.
    Krauth MT; Burgstaller S; Buxhofer-Ausch V; Gastl G; Geissler K; Keil F; Krippl P; Melchardt T; Petzer A; Rumpold H; Sliwa T; Wöhrer S; Wölfler A; Gisslinger H
    Wien Klin Wochenschr; 2018 Sep; 130(17-18):495-504. PubMed ID: 30043249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.